BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Curran D, de Ridder M, Van Effelterre T. The impact of assumptions regarding vaccine-induced immunity on the public health and cost-effectiveness of hepatitis A vaccination: Is one dose sufficient? Hum Vaccin Immunother 2016;12:2765-71. [PMID: 27428611 DOI: 10.1080/21645515.2016.1203495] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Souto FJD, de Brito WI, Fontes CJF. Impact of the single-dose universal mass vaccination strategy against hepatitis A in Brazil. Vaccine 2019;37:771-5. [DOI: 10.1016/j.vaccine.2018.12.054] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
2 Tsai PH, Tsai MS, Chiang YH, Shih CY, Liu CY, Chuang YC, Yang CJ. Effectiveness of hepatitis A vaccination among people living with HIV in Taiwan: Is one dose enough? J Microbiol Immunol Infect 2020:S1684-1182(20)30155-9. [PMID: 32690395 DOI: 10.1016/j.jmii.2020.06.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Andani A, van Damme P, Bunge EM, Salgado F, van Hoorn RC, Hoet B. One or two doses of hepatitis A vaccine in universal vaccination programs in children in 2020: A systematic review. Vaccine 2021:S0264-410X(21)00054-2. [PMID: 33526283 DOI: 10.1016/j.vaccine.2021.01.038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
4 Juliao P, Abadia I, Welby S, Wéry S, Wong D, De Léon T, DeAntonio R, Naranjo L, Guignard A, Marano C. Hepatitis A antibody persistence 8 and 10 years after 1-dose and 2-dose vaccination in children from Panama. Vaccine 2021;39:26-34. [PMID: 33239226 DOI: 10.1016/j.vaccine.2020.11.030] [Reference Citation Analysis]
5 Alberts CJ, Boyd A, Bruisten SM, Heijman T, Hogewoning A, Rooijen MV, Siedenburg E, Sonder GJB. Hepatitis A incidence, seroprevalence, and vaccination decision among MSM in Amsterdam, the Netherlands. Vaccine 2019;37:2849-56. [PMID: 30992222 DOI: 10.1016/j.vaccine.2019.03.048] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
6 Herzog C, Van Herck K, Van Damme P. Hepatitis A vaccination and its immunological and epidemiological long-term effects - a review of the evidence. Hum Vaccin Immunother 2021;17:1496-519. [PMID: 33325760 DOI: 10.1080/21645515.2020.1819742] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Guo Y, Zhang L, Feng D, Zhao S, Liu Q, Xu J, Lu M, Li J, Zhang Y, Guo W. The impact of universal live attenuated hepatitis A vaccines in Henan, China, 2005-2018. Int J Infect Dis 2020;93:163-7. [PMID: 32045695 DOI: 10.1016/j.ijid.2020.02.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Brouwer AF, Masters NB, Eisenberg JNS. Quantitative Microbial Risk Assessment and Infectious Disease Transmission Modeling of Waterborne Enteric Pathogens. Curr Environ Health Rep 2018;5:293-304. [PMID: 29679300 DOI: 10.1007/s40572-018-0196-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
9 Narayanan N, Elsaid MI, NeMoyer RE, Trivedi N, Zeb U, Rustgi VK. Disparities in hepatitis A virus (HAV) vaccination coverage among adult travelers to intermediate or high-risk countries: The role of birthplace and race/ethnicity. Vaccine 2019;37:4111-7. [PMID: 31196682 DOI: 10.1016/j.vaccine.2019.05.071] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
10 Zanella B, Boccalini S, Biamonte MA, Giorgetti D, Menicacci M, Bonito B, Ninci A, Tiscione E, Puggelli F, Mereu G, Working Group Dhs, Working Group AOUMeyer, Working Group Ausltc, Bonanni P, Bechini A. A Study of Hepatitis A Seroprevalence in a Paediatric and Adolescent Population of the Province of Florence (Italy) in the Period 2017-2018 Confirms Tuscany a Low Endemic Area. Vaccines (Basel) 2021;9:1194. [PMID: 34696301 DOI: 10.3390/vaccines9101194] [Reference Citation Analysis]